eISSN: 2081-2833
ISSN: 2081-0016
Medycyna Paliatywna/Palliative Medicine
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
4/2017
vol. 9
 
Share:
Share:
abstract:
Review paper

Chemotherapy-induced peripheral neuropathy as a clinical problem

Anna I. Ciszewska
,
Marcin Janecki
,
Angelika Copija
,
Ewa Nowakowska-Zajdel

Medycyna Paliatywna 2017; 9(4): 204–209
Online publish date: 2018/03/08
View full text Get citation
 
Chemotherapy-induced peripheral neuropathy (CIPN) is a common complication of oncological treatment, leading to a substantial decrease in the quality of life of patients with cancer. It is commonly responsible for reduced efficiency or even cessation of the treatment effect because the effective anticancer drug dose is reduced or discontinued.

Despite the fact that we know more and more about CIPN pathophysiological mechanisms, the predictive factors, prevention, and treatment options are still very limited. The pathomechanism, clinical symptoms, and potential treatment options based of differences between oncological drugs responsible for CIPN are presented in this review. The potential risk factors that may increase the likelihood of developing CIPN, such as genetic background, are also described. This has potential future impact on extracting the CIPN high-risk group of patients qualified to specific oncological treatment options.
keywords:

chemotherapy-induced peripheral neuropathy, pathomechanism, duloxetine

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.